Shanghai Henlius Biotech, Inc. Class H stock analysis
Want to see HK:2696 full AI Analyst Report?
Shanghai Henlius Biotech, Inc. Class H (2696) Stock Price & Analysis
2696 Stock Chart & Stats
- Day’s Range
- HKD 47.40 - HKD 50.00
- 52-Week Range
- HKD 45.50 - HKD 87.10
- Previous Close
- HKD 49.98
- Volume
- N/A
- Average Volume (3M)
- 780.15K
- Market Cap
- HKD 26.24B
- Enterprise Value
- HKD 38.71B
- Total Cash (Recent Filing)
- HKD 956.02M
- Total Debt (Recent Filing)
- HKD 3.95B
- Price to Earnings (P/E)
- 25.7
- Beta
- 0.66
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Sustained Profitability
Sustained profitability and high gross margins indicate that Henlius has moved beyond a purely development-stage profile. This provides internal funding capacity for pipeline investment, supports commercial resilience, and strengthens the durability of earnings as biologic sales expand.
Positive Cash Generation
Consistently positive operating cash flow, together with positive free cash flow in recent years, demonstrates that commercialization is generating meaningful cash. This improves financial self-funding capacity and reduces reliance on external capital for ongoing operations and development.
Improving Balance Sheet
The substantial reduction in debt relative to equity improves balance-sheet resilience compared with prior years. Lower leverage should give Henlius greater flexibility to fund growth, manage development spending, and absorb execution setbacks while profitability continues to mature.
Bears Say
Margin Compression
The 2025 decline in net and operating profitability suggests that higher costs or investment levels are reducing earnings leverage. If this persists, revenue growth may translate less efficiently into profit and could weaken the company’s ability to compound earnings.
Meaningful Leverage
Although debt-to-equity has improved, meaningful and historically volatile leverage leaves Henlius more sensitive to development or commercialization setbacks. Debt obligations can constrain capital allocation and increase the financial impact of weaker operating performance.
Uneven Free Cash Flow
The history of negative free cash flow and the renewed decline in 2025 show that cash outcomes remain sensitive to investment requirements. This uneven conversion can limit dependable internal funding and create greater variability in financing needs over time.
Shanghai Henlius Biotech, Inc. Class H News
Henlius Announces HANSIZHUANG and FUTUONING Additions to 2026 NRDL
Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) just unveiled an announcement. Shanghai Henlius Biotech develops oncology therapies, including HANSIZHUANG, its independently developed anti-PD-1 monoclonal antibody, and FUTUONING, an
2696 FAQ
What was Shanghai Henlius Biotech, Inc. Class H’s price range in the past 12 months?
What is Shanghai Henlius Biotech, Inc. Class H’s market cap?
When is Shanghai Henlius Biotech, Inc. Class H’s upcoming earnings report date?
How were Shanghai Henlius Biotech, Inc. Class H’s earnings last quarter?
Is Shanghai Henlius Biotech, Inc. Class H overvalued?
Does Shanghai Henlius Biotech, Inc. Class H pay dividends?
What is Shanghai Henlius Biotech, Inc. Class H’s EPS estimate?
How many shares outstanding does Shanghai Henlius Biotech, Inc. Class H have?
What happened to Shanghai Henlius Biotech, Inc. Class H’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Shanghai Henlius Biotech, Inc. Class H?
What is the TipRanks Smart Score and how is it calculated?
Shanghai Henlius Biotech, Inc. Class H Stock Smart Score
Company Description
Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise, dedicated to the research and advancement of biologic medicines, with a primary focus on cancer, autoimmune conditions, and ophthalmic disorders. Its commercial portfolio encompasses several approved biologic treatments. Specifically, it markets HANLIKANG, a rituximab injection utilized for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection indicated for breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection with indications in metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. In addition to its marketed products, Shanghai Henlius is actively progressing its robust development pipeline, which includes Serplulimab, undergoing further development for applications such as squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and a range of other solid tumor types. Among its other investigational compounds are HLX04-O, a bevacizumab injection aimed at wet age-related macular degeneration; HLX22 for breast and metastatic gastric cancer; a group of therapies—HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20—collectively aimed at solid tumors; HLX11 for breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12, addressing gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14, designed to treat osteoporosis. Further expanding its pipeline, HLX26 is being developed for solid tumors and lymphoma; HLX13 is under investigation for melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71, with potential for treating COVID-19. The firm conducts its operations across Mainland China, Europe, the broader Asia-Pacific region, and various other international territories. Founded in 2010, its headquarters are situated in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jun Zhu
- Employees
- 4,082
- Website
- www.henlius.com
- Address
- Building B8, Shanghai, SH, 200233, CN
Shanghai Henlius Biotech, Inc. Class H (2696) Earnings & Revenues
2696 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 5 | 15 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 0 | 0 | 12 |








